Last updated: April 22, 2026

Application No. 19/257,318

Untitled Application

Unknown

Filed

1600

Priority

Mar 06, 2023 — EU 23160259.0 +2 more

Examiner

SABILA, MERCY HELLEN

Art Unit

1654

Tech Center

Ascendis Pharma A/S

Assignee

Ascendis Pharma A/S

OA Round

1 (Non-Final)

This examiner grants 59% of cases after interview

— +45.7% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 257 resolved cases, 2023–2026

Examiner Intelligence

SABILA, MERCY HELLEN View full profile →

Grants 59% of resolved cases

Career Allowance Rate

152 granted / 257 resolved

-0.9% vs TC avg

Strong +46% interview lift

Without

With

+45.7%

Interview Lift

resolved cases with interview

Typical timeline

2y 8m

Avg Prosecution

56 currently pending

Career history

313

Total Applications

across all art units

Statute-Specific Performance

§101

3.2%

-36.8% vs TC avg

§103

42.0%

+2.0% vs TC avg

§102

15.9%

-24.1% vs TC avg

§112

20.7%

-19.3% vs TC avg

Black line = Tech Center average estimate • Based on career data from 257 resolved cases

Prosecution Timeline

1600

Application Filed

Mar 17, 2026

Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/267,891

Patent 12595286

FUCOSE-BINDING PROTEIN, METHOD FOR PRODUCING SAME, AND USE OF SAME

4y 11m to grant Granted Apr 07, 2026

17/434,616

Patent 12577282

GALECTIN-1/ GALECTIN-3 CHIMERAS AND MULTIVALENT PROTEINS

4y 6m to grant Granted Mar 17, 2026

17/284,608

Patent 12565516

CARRIER PROTEIN FOR IMPROVING PROPERTIES OF BIOACTIVE PROTEIN

4y 3m to grant Granted Mar 03, 2026

17/604,376

Patent 12534514

BIOLOGICAL AND SYNTHETIC MOLECULES INHIBITING RESPIRATORY SYNCYTIAL VIRUS INFECTION

4y 3m to grant Granted Jan 27, 2026

17/888,252

Patent 12528839

CONJUGATED VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTI-TUMOR IMMUNE REDIRECTORS

3y 5m to grant Granted Jan 20, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

59%

Grant Probability

99%

With Interview (+45.7%)

2y 8m

Median Time to Grant

Low

PTA Risk

Based on 257 resolved cases by this examiner. Grant probability derived from career allowance rate.